Abstract Number: 674 • 2014 ACR/ARHP Annual Meeting
A Novel Strategy to Identify and Evaluate Approved Drugs and Treatments for Repositioning As Therapies for Systemic Lupus Erythematosus (SLE)
Background/Purpose: Development of new SLE treatments has been slow with only one new treatment approved in the past half century. One way to increase the…Abstract Number: 673 • 2014 ACR/ARHP Annual Meeting
A Comparison of Rheumatoid Arthritis and Systemic Lupus Erythematosus Trial Design: Ways to Improve Positive Trials in Systemic Lupus Erythematosus
Background/Purpose: Recent SLE RCTs were examined and compared to rheumatoid arthritis (RA) RCT to suggest modifications to SLE RCTs that could improve the future success…Abstract Number: 672 • 2014 ACR/ARHP Annual Meeting
Favorable Response to Belimumab in Pediatric-Onset Systemic Lupus Erythematosus
Background/Purpose: Belimumab (Benlysta) is a human monoclonal antibody that inhibits soluble B-lymphocyte stimulator. It was approved by the FDA in 2011 for treatment of active,…Abstract Number: 671 • 2014 ACR/ARHP Annual Meeting
Belimumab Reduces the Frequency of Flares in Patients with Refractory SLE: DATA from Clinical Practice Setting
Background/Purpose To investigate the efficacy and safety of belimumab in patients affected with active systemic lupus erythematosus (SLE) refractory to standard therapy in the clinical…Abstract Number: 670 • 2014 ACR/ARHP Annual Meeting
Decreased Disease Activity and Corticosteroid Usage and No Renal Flares during Belimumab Treatment in Patients with Systemic Lupus Erythematosus
Background/Purpose B cells have a central role in Systemic Lupus Erythematosus (SLE) and autoantibody production. B-Lymphocyte Stimulator (BLyS) is important for the activation and maintenance…Abstract Number: 669 • 2014 ACR/ARHP Annual Meeting
Predicted Chronic Exposure and Dose Selection for Belimumab Administered Subcutaneously to SLE Patients
Background/Purpose: Monthly (q4w) intravenously (IV) administered belimumab 10 mg/kg is approved for the treatment of adults with active, autoantibody-positive SLE receiving standard therapy. The present…Abstract Number: 667 • 2014 ACR/ARHP Annual Meeting
24-Month Outcomes Associated with Belimumab in Patients with Systemic Lupus Erythematosus in Clinical Practice Settings
Background/Purpose: The clinical efficacy of belimumab in patients with systemic lupus erythematosus (SLE) has been demonstrated in large randomized clinical trials. We examined clinical outcomes…Abstract Number: 668 • 2014 ACR/ARHP Annual Meeting
Evolution of Patients with Systemic Lupus Erythematous Treated with Belimumab in Clinical Practice Settings
Background/Purpose After the approval of belimumab for patients with systemic lupus erythematosus (SLE), the objective of this study is to describe the clinical outcomes associated…Abstract Number: 666 • 2014 ACR/ARHP Annual Meeting
Approach to Discriminate Treatment Impact in Both Moderate and Severe SLE: The Atacicept Phase IIb Trial Design
Background/Purpose Increases in background treatment in SLE trials lead to high placebo group responses in patients with moderate but not those with high disease activity…Abstract Number: 665 • 2014 ACR/ARHP Annual Meeting
Safety and Efficiency of Low-Dose Interleukin-2 Treatment in Systemic Lupus Erythematosus
Background/Purpose Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by loss of tolerance to nuclear self-antigens, production of pathogenic autoantibodies and damage tomultiple organs.…Abstract Number: 664 • 2014 ACR/ARHP Annual Meeting
The Pathogenesis of Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Brain Intrinsic Factors
Background/Purpose: Neuropsychiatric disease is a common manifestation of systemic lupus erythematosus (SLE). Frequent presentations include depression, anxiety, memory loss and cognitive decline. The pathogenesis of…Abstract Number: 663 • 2014 ACR/ARHP Annual Meeting
STAT3 Inhibition Delays the Onset of Lupus Nephritis in MRL/Lpr Mice
Background/Purpose The transcription factor Signal transducer and activator of transcription (STAT) 3 is overexpressed and aberrantly activated in patients with SLE as well as lupus-prone…Abstract Number: 662 • 2014 ACR/ARHP Annual Meeting
Interferon Regulatory Factor-5 Promotes Disease in the MRL/Lpr Mouse Model of Lupus
Background/Purpose Interferon regulatory factor 5 (IRF5) polymorphisms are strongly associated with an increased risk of developing Systemic Lupus Erythematosus (SLE). SLE is caused, in part,…Abstract Number: 661 • 2014 ACR/ARHP Annual Meeting
Dysfunction of Glycosphingolipid Metabolism in Lupus Nephritis
Background/Purpose: Lupus is a chronic autoimmune disease characterized by autoantibody production and aberrant activation and proliferation of lymphocytes. Subsequent deposition of immune complexes in target…Abstract Number: 660 • 2014 ACR/ARHP Annual Meeting
Microthrombotic Renal Vascular Lesions Are Associated to Increased Renal Inflammatory Infiltration in a Mouse Model of Lupus Nephritis
Background/Purpose In patients with lupus nephritis (LN), acute renal vascular and atherosclerotic lesions correlate with the degree of inflammation regardless the presence of antiphospholipid antibodies.…
ACR Meeting Abstracts